These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18360567)

  • 1. Management of oxaliplatin-induced peripheral neuropathy.
    Saif MW; Reardon J
    Ther Clin Risk Manag; 2005 Dec; 1(4):249-58. PubMed ID: 18360567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
    Gamelin E; Gamelin L; Bossi L; Quasthoff S
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oxaliplatin neurotoxicity].
    Gamelin L; Boisdron-Celle M; Morel A; Gamelin E
    Bull Cancer; 2006 Feb; 93 Suppl 1():S17-22. PubMed ID: 16491518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy.
    Saif MW
    J Appl Res; 2004 Jan; 4(4):576-582. PubMed ID: 19816592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
    Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
    Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
    Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
    Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy].
    Taguchi K
    Yakugaku Zasshi; 2016; 136(2):287-96. PubMed ID: 26831807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    PLoS One; 2011 Apr; 6(4):e18469. PubMed ID: 21494615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy.
    Joseph EK; Chen X; Bogen O; Levine JD
    J Pain; 2008 May; 9(5):463-72. PubMed ID: 18359667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical Oxaliplatin Produces Gain- and Loss-of-Function in Multiple Classes of Sensory Afferents.
    Saleque N; Vastani N; Gentry C; Andersson DA; Israel MR; Bevan S
    J Pain; 2024 Jan; 25(1):88-100. PubMed ID: 37524219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.